| Fleet Landing | |
| One Fleet Landing Blvd, Atlantic Beach, Florida 32233 | |
| (904) 246-9900 | |
| Name | Fleet Landing |
|---|---|
| Location | One Fleet Landing Blvd, Atlantic Beach, Florida |
| Certified By | Medicare |
| No. of Certified Beds | 70 |
| Occupancy Rate | 71.57% |
| Medicare ID (CCN) | 105743 |
| Legal Business Name | Naval Continuing Care Retirement Foundation Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1992767057 |
| Organization Name | NAVAL CONTINUING CARE RETIREMENT FOUNDATION INCORPORATED |
| Doing Business As | FLEET LANDING |
| Address | 1 Fleet Landing Blvd, Atlantic Beach, FL 32233 |
| Phone Number | 904-246-9900 |
News Archive
Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A more holistic, less piecemeal roadmap for the use of chemicals in the state is the goal of research, industry and government leaders who will gather this week in the state's first green chemistry conference.
University at Buffalo researchers are the first to show that a controlled individualized exercise training program can bring athletes and others suffering with post-concussion syndrome (PCS) back to the playing field or to their daily activities.
The dentate gyrus of the hippocampus is part of the brain that helps form memories. It is also one of just two areas in the adult brain where new neurons are continuously formed.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A more holistic, less piecemeal roadmap for the use of chemicals in the state is the goal of research, industry and government leaders who will gather this week in the state's first green chemistry conference.
University at Buffalo researchers are the first to show that a controlled individualized exercise training program can bring athletes and others suffering with post-concussion syndrome (PCS) back to the playing field or to their daily activities.
The dentate gyrus of the hippocampus is part of the brain that helps form memories. It is also one of just two areas in the adult brain where new neurons are continuously formed.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.8 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.08 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 61.36 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 9.9 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.55 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.82 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.19 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.81 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.63 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.42 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.23 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.57 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 25 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.14 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.11 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 79.9 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.15 | 82.93 |
News Archive
Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.
A more holistic, less piecemeal roadmap for the use of chemicals in the state is the goal of research, industry and government leaders who will gather this week in the state's first green chemistry conference.
University at Buffalo researchers are the first to show that a controlled individualized exercise training program can bring athletes and others suffering with post-concussion syndrome (PCS) back to the playing field or to their daily activities.
The dentate gyrus of the hippocampus is part of the brain that helps form memories. It is also one of just two areas in the adult brain where new neurons are continuously formed.
› Verified 8 days ago